Pure Global AI
NCT06255743Recruiting

(Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-ds DNA Antibodies) and Relation to Depression and Anxiety in SLE

(Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies) Correlate With Depression and Anxiety in Systemic Lupus Erythematosus Patients
Sohag UniversityClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Systemic Lupus Erythematosus
Drug/Device/Intervention
Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Sohag University
Location
Sohag, Egypt
Timeline & enrollment
Phase
N/A
Start date
Feb 14, 2024
End date
Feb 14, 2025
Enrollment
50 participants
Primary outcome

the degree of depression,the degree of anxiety

Summary

the study determine the relation between the degree of (Depression and Anxiety) in Systemic
 Lupus Erythematosus Patients by zung self rating depression scale and zung self rating
 anxiety scale and (Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double
 Strad DNA Antibodies).

ICD-10 classifications
Systemic lupus erythematosusSystemic lupus erythematosus, unspecifiedLupus erythematosusSystemic lupus erythematosus with organ or system involvementOther forms of systemic lupus erythematosus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06255743
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06255743 through Pure Global AI's free database. This phase not specified trial is sponsored by Sohag University and is currently Recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.